Cargando…
Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
BACKGROUND: Patients with stage II nasopharyngeal carcinoma were reported to benefit from adding cisplatin-based concurrent chemotherapy to two-dimensional conventional radiotherapy. But this benefit becomes uncertain in the intensity-modulated radiotherapy (IMRT) era, owing to its significant advan...
Autores principales: | Zhang, Lu-Ning, Gao, Yuan-Hong, Lan, Xiao-Wen, Tang, Jie, Su, Zhen, Ma, Jun, Deng, Wuguo, OuYang, Pu-Yun, Xie, Fang-Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791283/ https://www.ncbi.nlm.nih.gov/pubmed/26528755 |
Ejemplares similares
-
Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Study
por: OuYang, Pu-Yun, et al.
Publicado: (2016) -
Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study
por: Lan, Xiao-Wen, et al.
Publicado: (2017) -
Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis
por: Liao, Jun-Fang, et al.
Publicado: (2019) -
Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
por: Liao, Jun-Fang, et al.
Publicado: (2019) -
The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy with or without concurrent chemotherapy: A propensity score‐matched analysis
por: Lai, YuLin, et al.
Publicado: (2022)